Search clinical trials for: Sintilimab Pegaspargase

Total 574 results

Fudan University

Recruiting

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Rong Tao

Recruiting

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Sun Yat-sen University

Recruiting

Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NK/T Cell Lymphoma Nos

China
Beijing Tiantan Hospital

Recruiting

Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Meningioma, Malignant

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
RemeGen Co., Ltd.

Recruiting

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Advanced Solid Tumours

China
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Zhejiang Cancer Hospital

Recruiting

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

SinTilimab After Radiation (STAR Study) (STAR)

Carcinoma, Non-Small Cell Lung

China
The First Hospital of Jilin University

Active, not recruiting

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer (STARS-RC03)

Locally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | Tislelizumab

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients (ORIENT-4)

Effect of Drugs

China
Sun Yat-sen University

Not yet recruiting

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL (SPENT)

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Shanghai YingLi Pharmaceutical Co. Ltd.

Recruiting

A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Children's Medical Center

Not yet recruiting

Study on Sintilimab in Stage IV High Risk Neuroblastoma (SCMC-S-2020)

Recurrent Stage IV High Risk Neuroblastoma

China
West China Hospital

Not yet recruiting

Sintilimab in FH-deficient Renal Cell Carcinoma

Renal Cell Carcinoma | Sintilimab | FH-deficient
M.D. Anderson Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Cancer of Unknown Primary

Cancer of Unknown Primary Site

United States
Henan Cancer Hospital

Active, not recruiting

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Wuhan University

Recruiting

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Pediatric Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...
First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaborators

Recruiting

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

Primary Central Nervous System Hodgkin Lymphoma

China
Henan Provincial People's Hospital

Not yet recruiting

Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Peking University Third Hospital; Dongzhimen Hospital, Beijing; Beijing Longfu...

Recruiting

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China
Sun Yat-sen University

Recruiting

Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL (ENKTL)

Extranodal NK/T-cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Guohui Li

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 | Immune Related Adverse Events

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

The Whole-course Management of Pegaspargase in ENKTL

Extranodal NK/T Cell Lymphoma

China
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Donafenib Plus Sintilimab for Advanced HCC

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Henan Cancer Hospital

Completed

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Extensive Disease Small Cell Lung Cancer

China
Shanghai Cancer Hospital, China

Unknown

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

Lung Neoplasms

China
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Shandong Cancer Hospital and Institute

Unknown

Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC (CONSIST)

Carcinoma, Non-Small Cell Lung

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
Rong Tao

Completed

Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients

Extranodal NK-T-Cell Lymphoma, Nasal Type

China

Search clinical trials for: Sintilimab Pegaspargase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations